Status:
COMPLETED
PAD. ICORG 05-01, V11
Lead Sponsor:
Cancer Trials Ireland
Conditions:
Multiple Myeloma and Plasma Cell Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin and dexamethasone, work in different w...
Detailed Description
OBJECTIVES: Primary * To assess the response (partial and complete response) in patients with relapsed or refractory multiple myeloma receiving bortezomib, doxorubicin hydrochloride, and dexamethaso...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- Patients aged at least 18 years with MM requiring therapy for relapsed or refractory disease.
- Previous VAD or VAD-like therapy (maximum 6 courses standard VAD). Subgroup allocation is shown in 4.1
- Measurable serum and/or urine paraprotein, or serum free light chain
- Performance Status (PS) 0-3 (ECOG - see Appendix B)
- Serum bilirubin values \<1.5 times the upper limit of normal
- Serum ALT/AST values \<2.5 times the upper limit of normal
- Able to give informed consent
- Exclusion criteria:
- Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
- Females of child-bearing potential without a negative pregnancy test, immediately prior to the start of PAD therapy and/or unwilling to use barrier contraceptive precautions throughout the study or who are pregnant or breast-feeding
- Men with partners of child bearing potential unwilling to use a medically acceptable form of contraception
- Patients with non-secretory MM and no measurable elevation of serum free light chain
- Performance status 4 (ECOG)
- Patient has a platelet count \<75 x 10\^9/L within 14 days before enrolment
- Patient has an absolute neutrophil count \<1.0 x 10\^9/L within 14 days before enrolment
- Patient has a serum creatinine \> 400 micromol/l at the time of enrolment
- Patient has Grade 2 or greater than Grade 2 peripheral neuropathy or neuropathic pain as defined by NCI Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) within 14 days before enrolment
- Cardiac ejection fraction \<40% by echocardiography or MUGA scan
- Known HIV seropositivity (obligatory testing is not necessary)
- Known Hepatitis B or C (obligatory testing is not necessary)
- Patients who have received more than one autologous transplant
- Use of any investigational drug within 4 weeks prior to enrolment or any patients scheduled to receive any investigational drug during the course of the study
- Previous Bortezomib therapy
- Patients who have a medical or psychiatric condition which, in the opinion of the investigator, contraindicates the patient's participation in this study
- Previous or concurrent malignancies at other sites, with the exception of appropriately treated localized epithelial skin or cervical cancer. Patients with remote histories (\>5 years) of other cured tumours may be entered
- Plasma exchange within 21 days of enrolment
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00814541
Start Date
December 1 2005
End Date
December 1 2012
Last Update
December 31 2014
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Dublin, Ireland, 24
2
Mater Misericordiae University Hospital
Dublin, Ireland, 7
3
St. James's Hospital
Dublin, Ireland, 8
4
University College Hospital
Galway, Ireland